J Cancer 2020; 11(5):1195-1202. doi:10.7150/jca.37321 This issue

Research Paper

Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer

Qing Xia1,2,3, Xu Zhang1,2,3, Qianqian Chen1,2,3, Xiangyun Chen1,2,3, Junliang Teng4, Changhui Wang1, Ming Li1,2,3✉, Lihong Fan1,2,3✉

1. Department of Respiratory Medicine, Shanghai 10th People's Hospital, Tongji University, Shanghai 200072, China.
2. Institute of Energy Metabolism and Health, Tongji University School of Medicine, Shanghai, China.
3. Institute of Development and Research of Holistic Integrative Medicine, Tongji University, Shanghai, China.
4. School of information management and engineering, Shanghai University of Finance and Economics, Shanghai, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Xia Q, Zhang X, Chen Q, Chen X, Teng J, Wang C, Li M, Fan L. Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer. J Cancer 2020; 11(5):1195-1202. doi:10.7150/jca.37321. Available from https://www.jcancer.org/v11p1195.htm

File import instruction

Abstract

Objective: Tissue factor (TF) is clinically identified as a marker for the detection of various types of cancer as well as the prediction of prognosis for cancer patients. This present study aims to explore the possibility and feasibility to use plasma TF as a biomarker for the prediction of prognosis of patients with non-small cell lung cancer (NSCLC).

Methods: A total of 100 patients with NSCLC at stage I to IV was included in the study, in whom the expression of plasma TF was detected. The Cox proportional-hazards regression model was then used to analyze the collected information, attempting to identify how patients' overall survival (OS) was associated with the expression of plasma TF. To verify the function of TF in invasion and metastasis, the expression of plasma TF was downregulated by SiRNA both in vivo and in vitro.

Results: The expression of plasma TF in NSCLC patients was related to the diagnosis age of the patient. It was noted that patients with high TF expression levels tended to have worse OS performance, which implied that TF could be used as a marker for patients with stage I-IV NSCLC (HR = 2.030, 95% CI = 1.21-3.398, P = 0.007). TF down-regulation inhibited the growth of tumor in vitro as well as the metastasis and invasion of NSCLC cells in vivo.

Conclusion: Both in vivo and in vitro, the invasion and migration of NSCLC cells are suppressed by TF knockdown. TF has the potential to become an effective biomarker for the prediction of prognosis of patients with stage I-IV NSCLC.

Keywords: non-small cell lung cancer (NSCLC), tissue factor, prognosis, biomarker